Meeting
2017 ASCO Annual Meeting
A phase 2 study to assess olaparib by homologous recombination deficiency status in patients with platinum-sensitive, relapsed, ovarian, fallopian tube, or primary peritoneal cancer.
Authors
Karen Anne Cadoo
Memorial Sloan Kettering Cancer Center and Weil Cornell Medical College, New York, NY
Karen Anne Cadoo , Carol Aghajanian , Cindy Fraser , Alvin Milner , Geert Kolvenbag
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02983799
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS5606)
DOI
10.1200/JCO.2017.35.15_suppl.TPS5606
Abstract #
TPS5606
Poster Bd #
425a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study.
First Author: Cara Amanda Mathews
Poster
2020 ASCO Virtual Scientific Program
Olaparib treatment in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Phase II LIGHT study.
First Author: Karen Anne Cadoo
Poster
2023 ASCO Annual Meeting
Oregovomab and non-platinum chemotherapy in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidates for platinum retreatment: A multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/APGOT-OV6).
First Author: JUNG-YUN LEE
Poster
2023 ASCO Annual Meeting
A randomized trial of olaparib, durvalumab, and cancer vaccine, UV1, as maintenance therapy in patients with BRCAwt with recurrent ovarian cancer: ENGOT-OV56/NSGO-CTU-DOVACC trial.
First Author: Mansoor Raza Mirza